Canagliflozin for the treatment of type 2 Diabetes Mellitus

Canagliflozin for the treatment of type 2 Diabetes Mellitus
Country
Agency
Status
Link
Details on adaptation process
Contact information
Croatia
AAZ
2014
Link to the summary
Summary of information from the report for decision makers and website
Mirjana Huic (Mirjana.Huic@aaz.hr)
Hungary
NIPN
Used to validate technology developer submission of evidence
NIPN (HUNHTAWP7@ogyei.gov.hu)
Italy
AIFA
Information missing. For further details, please contact Ingrid Wilbacher: ingrid.wilbacher@hvb.zoverz.at (WP3 LP) or Agnese Cangini a.cangini@aifa.gov.it
Agnese Cangini a.cangini@aifa.gov.it
Luxembourg
CMSS
Used in cross-checking evidence.
Yves Bruch yves.bruch@secu.lu
Malta
MEH
Used in direct decision-making.
Antonia Formosa antonia.formosa@gov.mt
Portugal
INFARMED
Used in cross-checking evidence.
João Martins joao.martins@infarmed.pt
Slovakia
MoH SK
Used in direct decision-making.
Tomas Tesar tomas.tesar@union.sk
Spain
AETSA
Published July 2015
Link to report In Spanish
The EUnetHTA assessment was adapted, i.e. systematic extraction of relevant HTA information from an existing joint assessment.
Teresa Molina Lopez mariat.molina.lopez@juntadeandalucia.es
Spain
MSSSI
Published June 2015
Link to report In Spanish
National Adaptation
Celia Juarez Rojo cjuarex@msssi.es
Sweden
TLV
Used in cross-checking evidence.
Johan Ponten johan.ponten@tlv.se
This website uses cookies to ensure you get the best experience on our website. By using the website you agree to our Privacy Policy and our Terms of Use.